NuCana plc (NCNA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

NuCana plc (NCNA) closed at USD 1.05 on 2026-10-14, a change of -75 % over the past year, with a market capitalization of USD 4.25M.

NuCana plc recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

NuCana plc key figures

Previous close

USD 1.05 (2026-10-14)

1-year change

-75 %

Market cap

USD 4.25M

Enterprise value

USD -14.44M

P/E ratio (trailing)

n/a

P/E ratio (forward)

-0.11

EPS (trailing)

0.00

EPS (forward)

-9.43

PEG ratio

n/a

Price to book

0.16

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.53

Employees

10

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About NuCana plc

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer; Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer; and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. It has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is based in Edinburgh, the United Kingdom.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for NuCana plc and compare it with other stocks.